Shares of Biotechnology company Masimo climbed 9.2% this morning. Here are some quick facts to get you started if you are interested in the stock:
-
Masimo has logged a -22.3% 52 week change, compared to 31.6% for the S&P 500
-
MASI has an average analyst rating of buy and is 14.79% away from its mean target price of $128.33 per share
-
Its trailing earnings per share (EPS) is $1.51, which brings its trailing Price to Earnings (P/E) ratio to 97.6. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $3.91 and its forward P/E ratio is 37.7
-
The company has a Price to Book (P/B) ratio of 5.7 in contrast to the Health Care sector's average P/B ratio is 4.08
-
The current ratio is currently 2.1, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
MASI has reported YOY quarterly earnings growth of -15.9% and gross profit margins of 0.5%
-
Masimo's revenues have an average growth rate of -4.3% with operating expenses growing at 0.1%. The company's current operating margins stand at -29.6%